Treatment of our NHL cell lines with the PI3K inhibitor LY294002 or the mTOR inhibitor Rapamycin led to a decrease in cell viability in all three cell lines with IC50 values in the range of around 1 μM for Rapamycin and 10 μM for LY294002 (Fig. 4; Table 1) demonstrating the importance of the PI3K pathway for survival of the cells. The gene discussed is MTOR; the disease is non-Hodgkin lymphoma.